Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $39,636 - $57,802
-11,010 Reduced 5.22%
200,000 $872,000
Q1 2023

May 15, 2023

SELL
$4.3 - $8.27 $1.16 Million - $2.23 Million
-269,691 Reduced 56.1%
211,010 $938,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $456,767 - $679,502
80,701 Added 20.18%
480,701 $4.05 Million
Q3 2022

Oct 28, 2022

BUY
$3.02 - $6.12 $1.21 Million - $2.45 Million
400,000 New
400,000 $2.45 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $22M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.